Crohn's & Colitis 360
Cure8 research brief
Why This Matters
Bowel urgency is a common, disruptive UC symptom; this trial analysis shows urgency improvements with etrasimod track with clinical remission, endoscopic improvement, better quality of life, and lower inflammatory biomarkers.
That suggests urgency may be a useful patient-reported marker of disease activity and treatment response.
Who Should Pay Attention
Adults with ulcerative colitis, patients considering or taking etrasimod or other S1P modulators, clinicians following UC treatment response, and researchers studying patient-reported outcomes and biomarkers.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This report links patient-reported bowel urgency to multiple conventional measures of disease activity (clinical remission and endoscopic improvement) and to biomarkers (fecal calprotectin, hs-CRP).
The data come from the ELEVATE UC 52 trial program and include results at Weeks 12 and 52; the article presents odds ratios and group comparisons rather than new prescribing guidance.
People with UC may find urgency an informative symptom to track alongside stool frequency, endoscopy, and biomarkers, but treatment decisions still depend on clinical evaluation and testing.
Keep In Mind
The article is an abstract-based analysis from a registered clinical trial (ELEVATE UC program, NCT03945188). Associations reported do not prove causation; findings reflect trial participants and should be interpreted alongside full study reports and clinical judgement.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCrohn's & Colitis 360
PublisherOxford University Press (OUP)
AuthorsMarla C Dubinsky, Erica R Cohen, Peter M Irving +8 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 16, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Current and novel biomarkers for predicting and assessing therapeutic response in inflammatory bowel disease: a systematic review.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Effectiveness and Safety of Mirikizumab in Patients With Moderate-to-severe Ulcerative Colitis: a Real-life Retrospective Multicenter Study
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.